Tag Archives: swiss biotech

News

Bachem reports excellent results for the first half-year 2021

  • Sales grow by 35.0% to CHF 239.1 million

  • EBITDA rises from CHF 53.0 million to CHF 75.5 million and a margin of 31.6%.

  • Operating income (EBIT) increases from CHF 40.3 million to CHF 61.9 million and a margin of 25.9%.

  • Net income rises from CHF 32.8 million to CHF 53.1 million and a margin of 22.2%.

  • Investments of over CHF 50 million and creation of 107 new jobs (77 of which are in Switzerland) since the beginning of the year.

Outlook:

  • Sales of CHF 500 million are now expected for the year 2021.

  • Bachem expects an average annual rate of growth of about 15% for the coming five years.

  • Bachem intends to grow operating income (EBIT) at a rate ahead of sales.

  • The company is now planning investments over CHF 500 million for the next five years across sites and business areas in order to further expand capacity.

Thomas Meier, CEO of Bachem, commented on the results of the past half-year: “The first half of 2021 has gone very well for Bachem. I am particularly pleased that we have been able to grow both our business, as well as our capacity and workforce simultaneously. Bachem is definitely on track to reach its company goals and continue to grow sustainably and profitably in the coming years.”

Group Results

The Bachem Group (SIX: BANB) increased its sales during the first half of 2021 in Swiss francs by 35.0% to CHF 239.1 million. Operating income before

depreciation and amortization (EBITDA) rose by 42.5% to CHF 75.5 million and operating income (EBIT) grew by 53.9% to CHF 61.9 million. This results in an EBITDA margin of 31.6% (first half-year 2020: 29.9%) and an EBIT margin of 25.9% (first half-year 2020: 22.7%). Net income increased by 61.8% to CHF 53.1 million and a margin of 22.2% (first half-year 2020: 18.5%).

Growth was registered across all product categories and sales regions with numerous approvals of customer products being a particularly welcome development. In the category Commercial API, sales rose by 35.8% compared to the first half of the year 2020 to CHF 148.2 million. In the category CMC Development growth was 30.7% to CHF 68.3 million. The Research & Specialties category grew by 43.7% to CHF 22.6 million. Split by sales regions, growth was 41.3% in Europe/Asia and 29.5% in North America (all growth figures in Swiss francs).

The expansion of the oligonucleotide business is proceeding according to plan. Additional oligonucleotide production facilities are scheduled to come on-stream at the Bubendorf location by the end of 2021. In the medium term Bachem is targeting annual sales of CHF 100 million in this area and a market position among the top three oligonucleotide contract development and manufacturing organizations (CDMOs).

Bachem is pursuing a global investment program of over CHF 500 million until 2026. During the first half of 2021, CHF 50.6 million were invested, primarily for the construction and expansion of new production capabilities. The specific investment sum is adjusted to medium-term growth expectations on an ongoing basis.

The complete half-year report 2021, including the slides for the analyst- and media conference can be downloaded under the following link:
www.bachem.com/about-bachem/investors-and-media/reports-and-presentations

Financial Calendar

March 18, 2022 Publication of Annual Report 2021 and Media and Financial Analyst Conference

April 27, 2022 Annual General Meeting (Financial Year 2021)

August 25, 2022 Publication of Half-Year Report 2022

Awards, EU, News

Bachem recognised as a winner at the Swiss Biotech Success Stories Awards 2021

Bachem is pleased to announce that the company has been recognised as one of the five winners of the Swiss Biotech Success Stories Awards 2021. 

They have been recognised for the value that they have consistently achieved for the past 50 years — a success story based on quality, innovation, sustainability and technological leadership. The company has grown over 50% in the last five years —  operating with sites across the world — and now offer more than 5,500 different biologically active peptides, amino acid derivatives and oligonucleotides.

The prestigious awards, bestowed by the Swiss Biotech Association, celebrate those who have made important and sustainable contributions to the biotech industry in Switzerland. Selected success stories such as Bachem are showcased to illustrate how Swiss biotech companies contribute to helping patients and improving health care worldwide. The award reflects Bachem’s passionate and unwavering support to their customers in discovering breakthrough medical advances that will significantly improve the life of patients.

It is important to celebrate these success stories and to show the world how vital biotechnology is for the future of humankind to survive and thrive. These life-changing innovations are a result of crucial scientific methods which need substantial financial and public support to keep moving forward.

Thomas Meier, CEO of Bachem AG, commented:

“I am happy that Bachem has won a Swiss Biotech Success Stories Award. Within fifty years, we have grown from a small company of two people to a leading provider for the world’s biopharmaceutical industry. This award is a testament to the team of talented and dedicated people that are the foundation of Bachem’s long-term success. I would like to thank the Swiss Biotech Association for this recognition.

We are proud of our strong Swiss heritage as we are of the strong global impact we can make for our customers and ultimately patients worldwide.

At Bachem, we take a long-term approach and continue to see broad-based growth, both in terms of products and geography. Despite the challenges of the ongoing COVID-19 pandemic, we continue to build new production capabilities and hire people across all our sites.”

Luca Bolliger, President of the Jury of Swiss Biotech Success Stories, commented:

“The tag for our initiative is Success Stories, but what we really mean is Value! Bachem is an entrepreneurial story that consistently created value for the last 50 years in Switzerland and abroad. Like with the current laureates and the one to come, it is important to celebrate valuable achievements within the life sciences ecosystem but it is also essential to share it with the public to educate, and the young generations as a palatable path forward for their future.”

Success categories

Bachem was chosen as a winner due to a number of success categories, including:

  • Completed achievement with lasting impact
  • Creation of jobs in Switzerland
  • Enabler for the biotech industry
  • Involvement of one or more Swiss citizens
  • Product approval and sustainable revenues
  • Swiss-based company / institution
  • Swissness: Think global, made in Switzerland

The company is honored to be recognized by the association and will attend the Swiss Biotech Day event on September 7 in Basel where the award will be collected personally.